Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.88 EUR | +0.73% |
|
+1.45% | +7.29% |
10:20am | EU court criticizes Commission over handling of COVID vaccine contracts | RE |
Jul. 16 | Emma Walmsley, CEO of GSK: Antimicrobial resistance, a public health issue | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 11.27 for the current year.
- The company has a low valuation given the cash flows generated by its activity.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.29% | 79.3B | - | ||
+61.53% | 848B | C+ | ||
+32.65% | 627B | B | ||
-3.66% | 363B | C+ | ||
+15.06% | 318B | B- | ||
+9.18% | 299B | C+ | ||
+12.27% | 234B | A+ | ||
+16.11% | 225B | B- | ||
+15.67% | 179B | C+ | ||
+2.47% | 167B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- GSK Stock
- GS71 Stock
- Ratings GSK plc